Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.54 |
| ▸ | BCL9 | O00512 | 8/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 8/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021958 | 0.89 | CNR1 (0.54) | CNR1BCL9CTNNB1FFAR4CNR2 | |
| SCHEMBL412179 | 0.86 | BCL9 (0.54) | CNR1BCL9CTNNB1FFAR4 | |
| SCHEMBL411076 | 0.85 | CNR1 (0.67) | CNR1MAP4K4CNR2 | |
| SCHEMBL412339 | 0.83 | CNR1 (0.52) | CNR1BCL9CTNNB1FFAR4CNR2 | |
| SCHEMBL2704405 | 0.81 | CNR1 (0.66) | CNR1MAP4K4FFAR4CNR2 | |
| SCHEMBL20021957 | 0.80 | ALOX5AP (0.47) | CNR1BCL9CTNNB1 | |
| SCHEMBL16554351 | 0.79 | CTSA (0.55) | CNR1MAP4K4 | |
| SCHEMBL410541 | 0.78 | CNR1 (0.52) | CNR1FFAR4CNR2 | |
| SCHEMBL23456310 | 0.78 | PIK3CD (0.49) | BCL9CTNNB1 | |
| SCHEMBL18165167 | 0.78 | PIK3CD (0.49) | BCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | CNR1 1005/4885BCL9 1/4885CTNNB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.